Svetislava J. Vukelja

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

Joyce O’Shaughnessy, David Miles, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2002 · 1.1K citations

Medicine, Oncology, Pharmacology +14

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology · 2010 · 960 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2010 · 764 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy et al. · Journal of Clinical Oncology · 2009 · 586 citations

Medicine, Oncology, Pharmacology +11

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology · 2012 · 544 citations

Medicine, Oncology, Pharmacology +17